- Home
- CRTO vs ZLAB Comparison
CRTO vs ZLAB Comparison
Compare CRTO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- ZLAB
- Stock Information
- Founded
- CRTO 2005
- ZLAB 2013
- Country
- CRTO France
- ZLAB China
- Employees
- CRTO N/A
- ZLAB N/A
- Industry
- CRTO Advertising
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- ZLAB Health Care
- Exchange
- CRTO Nasdaq
- ZLAB Nasdaq
- Market Cap
- CRTO 2.3B
- ZLAB 1.8B
- IPO Year
- CRTO 2013
- ZLAB 2017
- Fundamental
- Price
- CRTO $34.21
- ZLAB $31.24
- Analyst Decision
- CRTO Buy
- ZLAB Strong Buy
- Analyst Count
- CRTO 10
- ZLAB 4
- Target Price
- CRTO $53.78
- ZLAB $52.50
- AVG Volume (30 Days)
- CRTO 251.2K
- ZLAB 976.3K
- Earning Date
- CRTO 10-30-2024
- ZLAB 11-12-2024
- Dividend Yield
- CRTO N/A
- ZLAB N/A
- EPS Growth
- CRTO 1230.66
- ZLAB N/A
- EPS
- CRTO 1.65
- ZLAB N/A
- Revenue
- CRTO $1,956,857,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- CRTO N/A
- ZLAB $48.34
- Revenue Next Year
- CRTO $6.88
- ZLAB $47.12
- P/E Ratio
- CRTO $24.81
- ZLAB N/A
- Revenue Growth
- CRTO 1.64
- ZLAB 28.16
- 52 Week Low
- CRTO $22.10
- ZLAB $13.48
- 52 Week High
- CRTO $49.93
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- CRTO 56.27
- ZLAB 70.41
- Support Level
- CRTO $40.63
- ZLAB $31.52
- Resistance Level
- CRTO $43.76
- ZLAB $36.60
- Average True Range (ATR)
- CRTO 1.12
- ZLAB 1.36
- MACD
- CRTO 0.23
- ZLAB 0.34
- Stochastic Oscillator
- CRTO 74.54
- ZLAB 58.60
About CRTO Criteo S.A.
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.